low molecular weight-B cell growth factor

MW 12 kDa; major lymphokine promoting the growth of activated B cells; shares only limited homology with other known lymphokines; produced by antigen or mitogen-activated T-cells; see also B cell-activating factor (B cell growth factor)

Also Known As:

LMW-BCGF

Networked: 22 relevant articles (2 outcomes, 3 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
  - Intercellular Signaling Peptides and Proteins: 29768
    - Cytokines: 164289
      - Lymphokines: 811
        low molecular weight-B cell growth factor: 22
- Peptides: 82426
  - Intercellular Signaling Peptides and Proteins: 29768
    - Cytokines: 164289
      - Lymphokines: 811
        low molecular weight-B cell growth factor: 22
Biological Factors: 2472
- Intercellular Signaling Peptides and Proteins: 29768
  - Cytokines: 164289
    - Lymphokines: 811
      - low molecular weight-B cell growth factor: 22

Related Diseases

1.	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 02/15/1990 - "Effects of low molecular weight B-cell growth factor on proliferation of leukemic cells from children with B-cell precursor-acute lymphoblastic leukemia." 03/01/1988 - "However, LMW-BCGF- and CD19-mediated signals do not depend on the expression of sIg, since they were also observed on sIg-B-cell precursor acute lymphoblastic leukemia (ALL) cells. " 01/01/1990 - "Four samples of acute lymphoblastic leukemia (ALL) were treated with low molecular weight B-cell growth factor (15 kDa) and recruitment of aneuploid cells from G0 to G1 was found in all patients (from 19.3% to 84.9%). " 09/01/1989 - "Low molecular weight B-cell growth factor and recombinant interleukin-2 are together able to generate cytotoxic T lymphocytes with LAK activity from the bone marrow cells of children with acute lymphoblastic leukemia." 02/15/1990 - "Recently, low-molecular-weight B-cell growth factor (LMW-BCGF) has been reported to stimulate growth of leukemic cells from B-cell precursor-acute lymphoblastic leukemia (BCP-ALL). "
2.	Lymphoma (Lymphomas) 08/01/1990 - "Our results showed that in 6 of the 14 lymphomas with a chromosomally abnormal clone LMW-BCGF produced an increased frequency of abnormal mitosis. " 08/01/1990 - "Effect of a low-molecular-weight B cell growth factor on the proliferation of normal and neoplastic lymphocytes in lymphomas." 08/01/1990 - "The usefulness of low-molecular-weight B-cell growth factor (LMW-BCGF) for routine cytogenetic study of B cell non-Hodgkin lymphomas (NHL) was evaluated. " 01/01/1988 - "Our findings provide unique and direct evidence that (a) CD19 is expressed on leukemic B lineage lymphoid progenitor cells freshly obtained from B lineage acute lymphoblastic leukemia patients but not on normal myeloid, erythroid, megakaryocytic, or multilineage bone marrow progenitor cells; (b) ligation of CD19 with B43 MoAb induces sustained increases in [Ca2+]i when crosslinked and inhibits high-molecular weight B cell growth factor (HMW-BCGF)-induced proliferation of activated B cells without affecting their low-molecular weight B cell growth factor (LMW-BCGF) response; therefore CD19 may be a unique signal receptor; (c) HMW-BCGF and LMW-BCGF augment expression of CD19, which suggests that CD19 and BCGF receptors may be under coordinate regulatory control; (d) approximately two million B43 MoAb molecules per cell can be bound to target B lineage lymphoma cells with a Ka of 1.9 x 10(8)/mol/L; (e) CD19 can undergo B43 MoAb-induced internalization; and (f) the opportunity is thus provided for using anti-CD19 MoAb to deliver toxins to B lineage neoplastic cells for more effective treatment of high-risk leukemia/lymphoma patients."
3.	Hairy Cell Leukemia 05/01/1989 - "IFN-alpha is highly efficient in the therapy of hairy cell leukemia (HCL), and we confirm in the present study that IFN-alpha also inhibits the LMW-BCGF dependent proliferation of hairy cells in vitro. " 12/15/1990 - "Interferon (IFN)-alpha inhibits DNA synthesis stimulated by low molecular weight B-cell growth factor (BCGF) in hairy cells in vitro, suggesting that the therapeutic efficacy of IFN-alpha in hairy cell leukemia (HCL) involves growth inhibition of malignant B cells. "
4.	Leukemia 09/01/1989 - "Our hypothesis is that LMW-BCGF plus rIL-2 stimulates the proliferation and activation of CD3- precursors from the BM cells of children with acute leukemia to become CD3+ cells that have LAK activity. " 07/01/1987 - "Low molecular weight B cell growth factor induces proliferation of human B cell precursor acute lymphoblastic leukemias." 01/01/1988 - "Our findings provide unique and direct evidence that (a) CD19 is expressed on leukemic B lineage lymphoid progenitor cells freshly obtained from B lineage acute lymphoblastic leukemia patients but not on normal myeloid, erythroid, megakaryocytic, or multilineage bone marrow progenitor cells; (b) ligation of CD19 with B43 MoAb induces sustained increases in [Ca2+]i when crosslinked and inhibits high-molecular weight B cell growth factor (HMW-BCGF)-induced proliferation of activated B cells without affecting their low-molecular weight B cell growth factor (LMW-BCGF) response; therefore CD19 may be a unique signal receptor; (c) HMW-BCGF and LMW-BCGF augment expression of CD19, which suggests that CD19 and BCGF receptors may be under coordinate regulatory control; (d) approximately two million B43 MoAb molecules per cell can be bound to target B lineage lymphoma cells with a Ka of 1.9 x 10(8)/mol/L; (e) CD19 can undergo B43 MoAb-induced internalization; and (f) the opportunity is thus provided for using anti-CD19 MoAb to deliver toxins to B lineage neoplastic cells for more effective treatment of high-risk leukemia/lymphoma patients."
5.	Neoplasms (Cancer) 05/01/1989 - "The presence of this marker has been readily detected on the hairy cells of 10 of the 12 patients tested in this study; interestingly, for one of the negative cases, the tumor cells were unable to proliferate in response to LMW-BCGF. " 09/01/1989 - "This potentiating effect was also observed for a LMW-BCGF-dependent B cell tumor derived from a lymphocytic nodular lymphoma. " 05/15/1989 - "The tumor B lymphocytes were activated in vitro to synthesize paraprotein by pokeweed mitogen (PWM), and by low molecular weight B cell growth factor (BCGF). "

Related Drugs and Biologics

1.	low molecular weight-B cell growth factor
2.	Intercellular Signaling Peptides and Proteins (Growth Factors)
3.	Interferons
4.	DNA (Deoxyribonucleic Acid)
5.	Interleukin-3 (Interleukin 3)
6.	Interleukin-7 (Interleukin 7)
7.	Interleukin-6 (Interleukin 6)
8.	Interleukin-4 (Interleukin 4)
9.	Interleukin-2 (IL2)
10.	Interleukin-9 (Interleukin 9)

Related Therapies and Procedures

1.	Ligation
2.	Therapeutics